Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Comparison of Imidazole- and 2-Methyl Imidazole-Containing Farnesyl-Protein Transferase Inhibitors: Interaction with and Metabolism by Rat Hepatic Cytochrome P450s

Cuyue Tang, Masato Chiba, Joy Nishime, Jerome H. Hochman, I.-Wu Chen, Theresa M. Williams and Jiunn H. Lin
Drug Metabolism and Disposition June 2000, 28 (6) 680-686;
Cuyue Tang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masato Chiba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joy Nishime
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerome H. Hochman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I.-Wu Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa M. Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiunn H. Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Methylation at the 2-position of the imidazole ring of IBN (I), a 1, 5-substituted imidazole-containing compound, was carried out to minimize its inhibition of rat cytochrome P450 (CYP)3A activity. The resulting analog 2-MIBN (II) exhibited an inhibitory potency 70-fold weaker (Ki = 25 μM) than that of I (Ki = 0.3 μM) toward CYP3A, the major rat liver microsomal P450 isoform(s) for the metabolism of I and II by rat liver microsomes in the presence of NADPH. The structural modification did not switch the major metabolic pathways for I and II, but significantly decreased the affinity of II to the metabolizing enzyme(s) as reflected by the difference in theirKi values for CYP3A. Enzyme kinetic studies also demonstrated that I had a lower apparentKm (0.3 μM) than II (18 μM), but an apparent Vmax 14 times lower than II. This finding indicates that methylation at the imidazole ring reduced the affinity of the compound to CYP3A, but increased the catalytic capacity, turning I as a substrate of low Kmvalue but low capacity into a compound of highKm but high capacity for the metabolism. Our results suggest the significance of substrate concentration in comparing the metabolic stability of compounds with different kinetic parameters. Although higher intrinsic clearance is implied for I when the substrate concentration is below or close to itsKm value, higher metabolic rate was constantly seen with II over micromolar range. The different kinetic parameters of I and II may also explain the observation that no significant difference in pharmacokinetic behavior was seen after an i.v. administration of I and II to the rat.

Footnotes

  • Send reprint requests to: Cuyue Tang, Ph.D., Department of Drug Metabolism, Merck Research Laboratories, Sumneytown Pike, P.O. Box 4, WP75A-203, West Point, PA 19486-0004. E-mail:cuyue_tang{at}merck.com

  • Abbreviations used are::
    FTase
    farnesyl-protein transferase
    FTIs
    farnesyl-protein transferase inhibitors
    CYP
    cytochrome P450
    IBN
    4-{5-[4-(3-trifluromethoxyphenyl)-3-oxopiperazin-6-butyl-1-ylmethyl]-imidazol-1-ylmethyl}-benzonitrile
    2-MIBN
    4-{5-[4-(3-trifluromethoxyphenyl)-3-oxopiperazin-6-butyl-1-ylmethyl]-2-methyl-imidazol-1-ylmethyl}-benzonitrile
    LC-MS
    liquid chromatography-mass spectroscopy
    MS/MS
    tandem mass spectroscopy
    ES
    enzyme-substrate complex
    TFA
    trifluoroacetic acid
    • Received November 5, 1999.
    • Accepted March 9, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (6)
Drug Metabolism and Disposition
Vol. 28, Issue 6
1 Jun 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Imidazole- and 2-Methyl Imidazole-Containing Farnesyl-Protein Transferase Inhibitors: Interaction with and Metabolism by Rat Hepatic Cytochrome P450s
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Comparison of Imidazole- and 2-Methyl Imidazole-Containing Farnesyl-Protein Transferase Inhibitors: Interaction with and Metabolism by Rat Hepatic Cytochrome P450s

Cuyue Tang, Masato Chiba, Joy Nishime, Jerome H. Hochman, I.-Wu Chen, Theresa M. Williams and Jiunn H. Lin
Drug Metabolism and Disposition June 1, 2000, 28 (6) 680-686;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Comparison of Imidazole- and 2-Methyl Imidazole-Containing Farnesyl-Protein Transferase Inhibitors: Interaction with and Metabolism by Rat Hepatic Cytochrome P450s

Cuyue Tang, Masato Chiba, Joy Nishime, Jerome H. Hochman, I.-Wu Chen, Theresa M. Williams and Jiunn H. Lin
Drug Metabolism and Disposition June 1, 2000, 28 (6) 680-686;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cytochrome P450 4F11 in lung cancer
  • SLC49A4-mediated pyrilamine transport
  • Functional Characterization of 29 CYP4F2 Variants
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics